Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 673 for inoperable advanced endometrial cancer
2013-003469-32Phase 2Terminated
- Sponsor
- University College London
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in endometrial cancer (EC), sponsored by University College London. Primary endpoint: Progression-free survival rate at 6 months. Started Aug 2014; status: terminated.
02
Drugs
talazoparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2013-003469-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003469-32.